Specialty and generic drug makers focus on producing off-patent medicines, biosimilars, and niche therapies for targeted conditions. These companies provide lower-cost alternatives to branded drugs, playing a critical role in healthcare sector.

The industry benefits from aging populations and demand for affordable treatments, though pricing pressure, regulatory scrutiny, and patent litigation create ongoing challenges. Competition among generic providers is also intense, which can erode margins.

For income investors, dividends in this segment tend to be modest and less predictable compared to large-cap pharmaceuticals. However, select firms with diversified pipelines and disciplined cost management can support sustainable payouts.